UAE medical devices market: size, growth and outlook 2026–2032

A regional distribution hub with federal registration and emirate-level facility rules. Published estimates normalised to 2025 range from USD 1.9 bn to USD 3.2 bn; the Consulting Wallah central estimate is USD 2.9 bn, growing at about 6% a year to USD 4.3 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.

Growth is driven by medical tourism (691,000 medical tourists to Dubai in 2023) and private hospital network expansion; chronic disease burden (diabetes, CVD); MoHAP nationwide diabetes screening programme (Oct 2023); mandatory health insurance coverage expansion and government infrastructure spend (AED 5.7 bn federal health budget 2025; 10 new hospitals announced Jul 2024).

Context that matters for buyers and suppliers: EDE (Emirates Drug Establishment) became sole federal authority for device classification, market authorisation, import permits and vigilance, taking over 44 services from MOHAP (Dec 2025 / Jan 2026). EDE first-time registration government fees ~AED 16,100 (~USD 4,400); total project cost typically USD 15,000-50,000+ incl. LAR; registration valid 5 years. 350 unique suppliers serve 913 manufacturers in the EDE register; top 10 suppliers hold 33.7% of registrations. Dubai-based suppliers hold 63.5% of device registrations; Abu Dhabi 25.9%; domestic manufacturing 4.1%.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 1.9 bn–USD 3.2 bn; differences are mostly scope.

Included: capital equipment, implants, single-use consumables and IVD instruments and reagents. Excluded: pharmaceuticals, hospital IT, commodity PPE where reported separately. Publishers differ on whether IVD and consumables are included.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• EDE (Emirates Drug Establishment) became sole federal authority for device classification, market authorisation, import permits and vigilance, taking over 44 services from MOHAP (Dec 2025 / Jan 2026) (MedDeviceGuide)
• EDE first-time registration government fees ~AED 16,100 (~USD 4,400); total project cost typically USD 15,000-50,000+ incl. LAR; registration valid 5 years (MedDeviceGuide)
• 350 unique suppliers serve 913 manufacturers in the EDE register; top 10 suppliers hold 33.7% of registrations (MedDeviceGuide)
• Dubai-based suppliers hold 63.5% of device registrations; Abu Dhabi 25.9%; domestic manufacturing 4.1% (MedDeviceGuide)
• United States is the largest country of origin at 16.0% of registrations (MedDeviceGuide)
• Device registrations peaked at 810 in 2021; 400 in 2025; 38 in Jan-May 2026 (MedDeviceGuide)
• PureHealth committed AED 13 bn to local procurement over the next decade (May 2024) (TechSci Research)
• Devices must be approved by MoHAP (now EDE) or relevant health authority before commercialisation; DoH Abu Dhabi enforces standardised equipment regulations (Fortune Business Insights; TechSci)

Where the GCC and India sit

• Abu Dhabi: largest emirate market (2025) — TechSci Research
• UAE federal budget for healthcare & community protection: AED 5.7 bn (2025) — UAE Cabinet via TechSci
• Dubai medical tourists: 691,000 (2023) — DHA via TechSci
• Active device rows in EDE register: 4,793 (of 16,939 products) (2026) — MedDeviceGuide

Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation

Opportunities we see: eDE multi-agent rule (Feb 2026) ends single-distributor model, opening room for new distributors; free zones (DHCC, JAFZA) with 100% foreign ownership for regional distribution hubs; iVD largest segment; dental and clinics fastest growth.

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Manufacturers and exporters: registration first, local partner second, tender readiness third — see what GCC buyers need.
• Hospital leaders: total cost of ownership (service, consumables, software) outweighs purchase price; tender the bundle.
• Investors: local assembly and distribution platforms backed by procurement preference.

1. Fortune Business Insights, UAE Medical Devices Market Size, Share & Industry Analysis 2032 — fortunebusinessinsights.com
2. TechSci Research, UAE Medical Devices Market Forecast 2031 — techsciresearch.com
3. MedDeviceGuide, UAE EDE Medical Device Supplier Concentration & Market Entry Analysis 2026 — meddeviceguide.com
4. MedDeviceGuide, UAE EDE Medical Device Registration Guide 2026 — meddeviceguide.com
5. MOHAP, Registration of a Medical Equipment — mohap.gov.ae
6. Fortune Business Insights (2026-10) — USD 3.01 bn (2025 est. USD 3.18 bn) (2024) to USD 4.71 bn (2032), CAGR 5.8% (2025-2032); scope: country / all medical devices incl. IVD — source
7. TechSci Research (2026) — USD 1.94 bn (2025) to USD 2.78 bn (2031), CAGR 6.18% (2026-2031); scope: country / medical devices (narrower scope); page also cites Mecomed USD 2.61 bn for 2024 — source
8. Mecomed (cited by TechSci) (2024) — USD 2.61 bn (2024) to — (), CAGR —; scope: country / medical devices segment, industry association estimate — source
9. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
10. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.